Premium
Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative
Author(s) -
Ellis Kathryn A.,
Rowe Christopher C.,
Villemagne Victor L.,
Martins Ralph N.,
Masters Colin L.,
Salvado Olivier,
Szoeke Cassandra,
Ames David
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.03.009
Subject(s) - neuroimaging , alzheimer's disease neuroimaging initiative , dementia , neuropsychology , magnetic resonance imaging , positron emission tomography , medicine , disease , psychology , population , cognitive decline , gerontology , cognition , psychiatry , neuroscience , radiology , environmental health
The Australian Imaging Biomarkers and Lifestyle (AIBL) study is a longitudinal study of 1112 volunteers from healthy, mild cognitive impairment, and Alzheimer's disease (AD) populations who can be assessed and followed up for prospective research into aging and AD. AIBL aims to improve understanding of the pathogenesis, early clinical manifestation, and diagnosis of AD, and identify diet and lifestyle factors that influence the development of AD. For AIBL, the magnetic resonance imaging parameters of Alzheimer's Disease Neuroimaging Initiative (ADNI) were adopted and the Pittsuburgh compound B ( 11 C‐PiB) positron emission tomography (PET) acquisition and neuropsychological tests were designed to permit comparison and pooling with ADNI data. Differences to ADNI include assessment every 18‐months, imaging in 25% (magnetic resonance imaging, 11 C‐PiB PET but no fluorodeoxyglucose PET), more comprehensive neuropsychological testing, and detailed collection of diet and lifestyle data. AIBL has completed the first 18‐month follow‐up and is making imaging and clinical data available through the ADNI website. Cross‐sectional analysis of baseline data is revealing links between cognition, brain amyloid burden, structural brain changes, biomarkers, and lifestyle.